NAMS Menopause Certification Master Exam Prep
Updated 2026 | 350+ Practice Questions & Verified
Answers | Advanced Menopause Society
Certification Study Guide, Women's Midlife Health
Review, Hormone Therapy (HT), Perimenopause,
Postmenopause, Vasomotor Symptoms,
Genitourinary Syndrome of Menopause (GSM),
Osteoporosis, Cardiometabolic Health, Sexual
Health, Clinical Guidelines, Detailed Rationales
Question 1: A 52-year-old perimenopausal woman reports moderate-to-severe
hot flashes that are significantly impacting her sleep and work performance.
She has a history of a pulmonary embolism five years ago following a knee
surgery. She is interested in non-hormonal options. Which of the following is
the MOST appropriate first-line FDA-approved non-hormonal pharmacological
agent for the treatment of her vasomotor symptoms?
A. Gabapentin
B. Selective Serotonin Reuptake Inhibitor (SSRI)
C. Oxybutynin
D. Clonidine
CORRECT ANSWER: B. Selective Serotonin Reuptake Inhibitor (SSRI)
Rationale: For women with a contraindication to hormone therapy, such as a history of
venous thromboembolism, SSRIs and serotonin-norepinephrine reuptake inhibitors
(SNRIs) are recommended as first-line non-hormonal pharmacological options.
Paroxetine is the only non-hormonal medication FDA-approved specifically for VMS;
other SSRIs/SNRIs are used off-label with strong evidence. Gabapentin and oxybutynin
are also options but are considered second-line. Clonidine has shown limited efficacy
and is generally not recommended as a first-line agent.
Question 2: A 48-year-old woman presents with vaginal dryness, dyspareunia,
and recurrent urinary tract infections. She is postmenopausal and has a
history of estrogen receptor-positive breast cancer treated with tamoxifen.
What is the MOST appropriate treatment recommendation for her
genitourinary syndrome of menopause (GSM)?
A. Systemic hormone therapy with oral estradiol
B. Vaginal estrogen cream
C. Vaginal moisturizers and lubricants, including a prescription vaginal
dehydroepiandrosterone (DHEA) suppository
D. Systemic hormone therapy with a transdermal estradiol patch
CORRECT ANSWER: C. Vaginal moisturizers and lubricants, including a
prescription vaginal dehydroepiandrosterone (DHEA) suppository
,Rationale: In breast cancer survivors, particularly those on aromatase inhibitors or
tamoxifen, systemic hormone therapy is contraindicated. For GSM, non-hormonal
moisturizers and lubricants are first-line. If these are insufficient, vaginal DHEA
(prasterone) is an FDA-approved option for dyspareunia in this population and is not
associated with systemic estrogen effects. Low-dose vaginal estrogen is generally
avoided in women with estrogen-sensitive cancers, especially if they are on aromatase
inhibitors, though some specialists may consider it after a shared decision-making
discussion.
Question 3: Which of the following metabolic changes is MOST
characteristically associated with the menopausal transition, independent of
chronological aging?
A. Decreased total cholesterol and LDL-cholesterol levels
B. Increased accumulation of visceral adipose tissue
C. Decreased fasting plasma glucose and improved insulin sensitivity
D. Decreased blood pressure and reduced risk of hypertension
CORRECT ANSWER: B. Increased accumulation of visceral adipose tissue
Rationale: The menopausal transition is associated with a shift in fat distribution from a
gynoid to an android pattern, leading to an increase in visceral adipose tissue. This
change is driven by estrogen withdrawal and is independent of age. This shift
contributes to an adverse metabolic profile, including increased LDL-cholesterol,
decreased HDL-cholesterol, insulin resistance, and an elevated risk of metabolic
syndrome and cardiovascular disease.
Question 4: A 55-year-old woman who is 7 years postmenopausal is concerned
about her bone health. Her DXA scan reveals a T-score of -2.7 at the lumbar
spine. She is otherwise healthy and has no history of fractures. What is the
MOST appropriate next step in her management?
A. Reassurance and lifestyle modifications, with a repeat DXA in 2 years
B. Initiate oral alendronate therapy
C. Initiate denosumab therapy
D. Initiate raloxifene therapy
CORRECT ANSWER: B. Initiate oral alendronate therapy
Rationale: A T-score of -2.5 or lower at the spine, femoral neck, or total hip is
diagnostic of osteoporosis. This patient meets criteria for treatment with a
bisphosphonate, such as alendronate, which is a first-line agent for osteoporosis.
Lifestyle modifications alone are insufficient for a T-score of -2.7. While denosumab is
an option, alendronate is generally the initial treatment of choice for its efficacy, safety,
,and low cost. Raloxifene is used for prevention and treatment of osteoporosis in
postmenopausal women but is less potent than bisphosphonates.
Question 5: A 51-year-old woman with a history of severe migraine with aura
is considering menopausal hormone therapy for bothersome VMS. Which
formulation and route of administration would be the SAFEST choice
concerning her migraine history?
A. Oral conjugated equine estrogens 0.625 mg daily
B. Transdermal estradiol 0.05 mg patch, changed twice weekly
C. Oral micronized estradiol 2 mg daily
D. Oral estradiol valerate 2 mg daily
CORRECT ANSWER: B. Transdermal estradiol 0.05 mg patch, changed twice
weekly
Rationale: Transdermal estrogen is preferred in women with migraine with aura
because it avoids the first-pass hepatic effect, resulting in more stable serum estrogen
levels and a lower risk of stroke compared to oral estrogens. Fluctuating hormone levels,
particularly during the hormone-free interval, can trigger migraine episodes.
Transdermal patches provide a continuous release, minimizing this risk. Oral estrogens
are associated with an increased risk of venous thromboembolism and stroke,
particularly in the presence of migraine with aura.
Question 6: A 49-year-old woman reports poor sleep, mood swings, and
difficulty concentrating. Her menstrual cycles have become irregular. She is
asking about hormone therapy. What is the PRIMARY rationale for potentially
initiating hormone therapy in this patient, considering her presenting
symptoms?
A. To prevent coronary heart disease
B. To treat the vasomotor symptoms and improve sleep, mood, and cognition
C. To prevent osteoporosis, as she is now at high risk
D. To manage her irregular cycles by regulating her menstrual periods
CORRECT ANSWER: B. To treat the vasomotor symptoms and improve sleep,
mood, and cognition
Rationale: The primary indication for hormone therapy is the treatment of moderate-
to-severe vasomotor symptoms (hot flashes and night sweats). The improved sleep,
mood, and cognitive function are secondary benefits resulting from the relief of VMS.
Hormone therapy is not indicated for the primary prevention of coronary heart disease.
Osteoporosis prevention is a secondary indication. Hormone therapy is not used to
regulate menstrual cycles in perimenopause.
, Question 7: Which of the following is the MOST significant risk factor for the
development of venous thromboembolism (VTE) in a postmenopausal woman
using hormone therapy?
A. Route of administration (transdermal vs. oral)
B. The specific progestin used in the regimen
C. Age at initiation of hormone therapy
D. Duration of hormone therapy use
CORRECT ANSWER: A. Route of administration (transdermal vs. oral)
Rationale: The route of estrogen administration is the most significant factor
influencing VTE risk in hormone therapy users. Oral estrogen is associated with a higher
risk of VTE due to the first-pass hepatic effect, which increases the production of
clotting factors and decreases antithrombin III. Transdermal estradiol is not associated
with a significant increase in VTE risk at standard doses, making it the preferred route
for women at higher risk.
Question 8: A 53-year-old postmenopausal woman who is a smoker with a
body mass index (BMI) of 34 kg/m² is asking about hormonal options for her
severe hot flashes. What is the MOST appropriate and safest hormonal
strategy?
A. Oral conjugated equine estrogens 0.625 mg with medroxyprogesterone acetate 2.5
mg daily
B. Transdermal estradiol 0.05 mg patch plus a progestin-releasing intrauterine device
(IUD)
C. Oral estradiol 2 mg daily with micronized progesterone 100 mg daily
D. Tibolone 2.5 mg daily
CORRECT ANSWER: B. Transdermal estradiol 0.05 mg patch plus a progestin-
releasing intrauterine device (IUD)
Rationale: This patient has multiple risk factors for VTE, including smoking and obesity.
The safest hormonal option is to use a transdermal estrogen, which avoids the first-pass
hepatic effect and does not increase VTE risk. To provide endometrial protection, a
progestin is required. A progestin-releasing IUD provides this protection, is highly
effective, and has a lower risk of breast cancer compared to oral progestins in some
studies.
Question 9: A 60-year-old woman was started on estrogen plus progestin
therapy (EPT) 3 years ago for VMS and has been doing well. She now asks if
she can continue it long-term. What is the MOST important element to
consider regarding the duration of her hormone therapy?
Updated 2026 | 350+ Practice Questions & Verified
Answers | Advanced Menopause Society
Certification Study Guide, Women's Midlife Health
Review, Hormone Therapy (HT), Perimenopause,
Postmenopause, Vasomotor Symptoms,
Genitourinary Syndrome of Menopause (GSM),
Osteoporosis, Cardiometabolic Health, Sexual
Health, Clinical Guidelines, Detailed Rationales
Question 1: A 52-year-old perimenopausal woman reports moderate-to-severe
hot flashes that are significantly impacting her sleep and work performance.
She has a history of a pulmonary embolism five years ago following a knee
surgery. She is interested in non-hormonal options. Which of the following is
the MOST appropriate first-line FDA-approved non-hormonal pharmacological
agent for the treatment of her vasomotor symptoms?
A. Gabapentin
B. Selective Serotonin Reuptake Inhibitor (SSRI)
C. Oxybutynin
D. Clonidine
CORRECT ANSWER: B. Selective Serotonin Reuptake Inhibitor (SSRI)
Rationale: For women with a contraindication to hormone therapy, such as a history of
venous thromboembolism, SSRIs and serotonin-norepinephrine reuptake inhibitors
(SNRIs) are recommended as first-line non-hormonal pharmacological options.
Paroxetine is the only non-hormonal medication FDA-approved specifically for VMS;
other SSRIs/SNRIs are used off-label with strong evidence. Gabapentin and oxybutynin
are also options but are considered second-line. Clonidine has shown limited efficacy
and is generally not recommended as a first-line agent.
Question 2: A 48-year-old woman presents with vaginal dryness, dyspareunia,
and recurrent urinary tract infections. She is postmenopausal and has a
history of estrogen receptor-positive breast cancer treated with tamoxifen.
What is the MOST appropriate treatment recommendation for her
genitourinary syndrome of menopause (GSM)?
A. Systemic hormone therapy with oral estradiol
B. Vaginal estrogen cream
C. Vaginal moisturizers and lubricants, including a prescription vaginal
dehydroepiandrosterone (DHEA) suppository
D. Systemic hormone therapy with a transdermal estradiol patch
CORRECT ANSWER: C. Vaginal moisturizers and lubricants, including a
prescription vaginal dehydroepiandrosterone (DHEA) suppository
,Rationale: In breast cancer survivors, particularly those on aromatase inhibitors or
tamoxifen, systemic hormone therapy is contraindicated. For GSM, non-hormonal
moisturizers and lubricants are first-line. If these are insufficient, vaginal DHEA
(prasterone) is an FDA-approved option for dyspareunia in this population and is not
associated with systemic estrogen effects. Low-dose vaginal estrogen is generally
avoided in women with estrogen-sensitive cancers, especially if they are on aromatase
inhibitors, though some specialists may consider it after a shared decision-making
discussion.
Question 3: Which of the following metabolic changes is MOST
characteristically associated with the menopausal transition, independent of
chronological aging?
A. Decreased total cholesterol and LDL-cholesterol levels
B. Increased accumulation of visceral adipose tissue
C. Decreased fasting plasma glucose and improved insulin sensitivity
D. Decreased blood pressure and reduced risk of hypertension
CORRECT ANSWER: B. Increased accumulation of visceral adipose tissue
Rationale: The menopausal transition is associated with a shift in fat distribution from a
gynoid to an android pattern, leading to an increase in visceral adipose tissue. This
change is driven by estrogen withdrawal and is independent of age. This shift
contributes to an adverse metabolic profile, including increased LDL-cholesterol,
decreased HDL-cholesterol, insulin resistance, and an elevated risk of metabolic
syndrome and cardiovascular disease.
Question 4: A 55-year-old woman who is 7 years postmenopausal is concerned
about her bone health. Her DXA scan reveals a T-score of -2.7 at the lumbar
spine. She is otherwise healthy and has no history of fractures. What is the
MOST appropriate next step in her management?
A. Reassurance and lifestyle modifications, with a repeat DXA in 2 years
B. Initiate oral alendronate therapy
C. Initiate denosumab therapy
D. Initiate raloxifene therapy
CORRECT ANSWER: B. Initiate oral alendronate therapy
Rationale: A T-score of -2.5 or lower at the spine, femoral neck, or total hip is
diagnostic of osteoporosis. This patient meets criteria for treatment with a
bisphosphonate, such as alendronate, which is a first-line agent for osteoporosis.
Lifestyle modifications alone are insufficient for a T-score of -2.7. While denosumab is
an option, alendronate is generally the initial treatment of choice for its efficacy, safety,
,and low cost. Raloxifene is used for prevention and treatment of osteoporosis in
postmenopausal women but is less potent than bisphosphonates.
Question 5: A 51-year-old woman with a history of severe migraine with aura
is considering menopausal hormone therapy for bothersome VMS. Which
formulation and route of administration would be the SAFEST choice
concerning her migraine history?
A. Oral conjugated equine estrogens 0.625 mg daily
B. Transdermal estradiol 0.05 mg patch, changed twice weekly
C. Oral micronized estradiol 2 mg daily
D. Oral estradiol valerate 2 mg daily
CORRECT ANSWER: B. Transdermal estradiol 0.05 mg patch, changed twice
weekly
Rationale: Transdermal estrogen is preferred in women with migraine with aura
because it avoids the first-pass hepatic effect, resulting in more stable serum estrogen
levels and a lower risk of stroke compared to oral estrogens. Fluctuating hormone levels,
particularly during the hormone-free interval, can trigger migraine episodes.
Transdermal patches provide a continuous release, minimizing this risk. Oral estrogens
are associated with an increased risk of venous thromboembolism and stroke,
particularly in the presence of migraine with aura.
Question 6: A 49-year-old woman reports poor sleep, mood swings, and
difficulty concentrating. Her menstrual cycles have become irregular. She is
asking about hormone therapy. What is the PRIMARY rationale for potentially
initiating hormone therapy in this patient, considering her presenting
symptoms?
A. To prevent coronary heart disease
B. To treat the vasomotor symptoms and improve sleep, mood, and cognition
C. To prevent osteoporosis, as she is now at high risk
D. To manage her irregular cycles by regulating her menstrual periods
CORRECT ANSWER: B. To treat the vasomotor symptoms and improve sleep,
mood, and cognition
Rationale: The primary indication for hormone therapy is the treatment of moderate-
to-severe vasomotor symptoms (hot flashes and night sweats). The improved sleep,
mood, and cognitive function are secondary benefits resulting from the relief of VMS.
Hormone therapy is not indicated for the primary prevention of coronary heart disease.
Osteoporosis prevention is a secondary indication. Hormone therapy is not used to
regulate menstrual cycles in perimenopause.
, Question 7: Which of the following is the MOST significant risk factor for the
development of venous thromboembolism (VTE) in a postmenopausal woman
using hormone therapy?
A. Route of administration (transdermal vs. oral)
B. The specific progestin used in the regimen
C. Age at initiation of hormone therapy
D. Duration of hormone therapy use
CORRECT ANSWER: A. Route of administration (transdermal vs. oral)
Rationale: The route of estrogen administration is the most significant factor
influencing VTE risk in hormone therapy users. Oral estrogen is associated with a higher
risk of VTE due to the first-pass hepatic effect, which increases the production of
clotting factors and decreases antithrombin III. Transdermal estradiol is not associated
with a significant increase in VTE risk at standard doses, making it the preferred route
for women at higher risk.
Question 8: A 53-year-old postmenopausal woman who is a smoker with a
body mass index (BMI) of 34 kg/m² is asking about hormonal options for her
severe hot flashes. What is the MOST appropriate and safest hormonal
strategy?
A. Oral conjugated equine estrogens 0.625 mg with medroxyprogesterone acetate 2.5
mg daily
B. Transdermal estradiol 0.05 mg patch plus a progestin-releasing intrauterine device
(IUD)
C. Oral estradiol 2 mg daily with micronized progesterone 100 mg daily
D. Tibolone 2.5 mg daily
CORRECT ANSWER: B. Transdermal estradiol 0.05 mg patch plus a progestin-
releasing intrauterine device (IUD)
Rationale: This patient has multiple risk factors for VTE, including smoking and obesity.
The safest hormonal option is to use a transdermal estrogen, which avoids the first-pass
hepatic effect and does not increase VTE risk. To provide endometrial protection, a
progestin is required. A progestin-releasing IUD provides this protection, is highly
effective, and has a lower risk of breast cancer compared to oral progestins in some
studies.
Question 9: A 60-year-old woman was started on estrogen plus progestin
therapy (EPT) 3 years ago for VMS and has been doing well. She now asks if
she can continue it long-term. What is the MOST important element to
consider regarding the duration of her hormone therapy?
